Sonia M. Rosenfield

Sonia M. Rosenfield

Auto-generated profile, based on publicly available information

Sonia M. Rosenfield

Division of Cancer Control and Population Sciences, National Cancer Institute, National Institutes of Health, U.S. Department of Health and Human Services , Bethesda, MD, USA

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
FSFrancisco R. Saenz
Francisco R. Saenz
VOVirginie Ory
Virginie Ory
MAMaram AlOtaiby
Maram AlOtaiby
SRSonia Rosenfield
Sonia Rosenfield
MFMary Furlong
Mary Furlong
ARAnna T Riegel
Anna T Riegel
Mammary epithelial (ME) cells cultured under conventional conditions senesce after several passages. Here, we demonstrate that mouse ME cells isolated from normal mammary glands or from mouse mammary tumor virus (MMTV)-Neu–induced mammary tumors, can be cultured indefinitely as conditionally reprogrammed cells (CRCs) on irradiated fibroblasts in the presence of the Rho kinase inhibitor Y-27632. Cell surface progenitor-associated markers are rapidly induced in normal mouse ME-CRCs relative to ME cells. However, the expression of certain mammary progenitor subpopulations, such as CD49f+ ESA+ CD44+, drops significantly in later passages. Nevertheless, mouse ME-CRCs grown in a three-dimensional extracellular matrix gave rise to mammary acinar structures. ME-CRCs isolated from MMTV-Neu transgenic mouse mammary tumors express high levels of HER2/neu, as well as tumor-initiating cell markers, such as CD44+, CD49f+, and ESA+ (EpCam). These patterns of expression are sustained in later CRC passages. Early and late passage ME-CRCs from MMTV-Neu tumors that were implanted in the mammary fat pads of syngeneic or nude mice developed vascular tumors that metastasized within 6 weeks of transplantation. Importantly, the histopathology of these tumors was indistinguishable from that of the parental tumors that develop in the MMTV-Neu mice. Application of the CRC system to mouse mammary epithelial cells provides an attractive model system to study the genetics and phenotype of normal and transformed mouse epithelium in a defined culture environment and in vivo transplant studies.

7 August 2024 in JNCI Monographs
Verified
Journal Article
Open access
PDF file
AEand Gary L. Ellison
and Gary L. Ellison
KHKathy J Helzlsouer
Kathy J Helzlsouer
SRSonia M Rosenfield
Sonia M Rosenfield
YKYun Kim
Yun Kim
RARebecca L Ashare
Rebecca L Ashare
DZDylan M Zylla
Dylan M Zylla
Background: The legal climate for cannabis use has dramatically changed with an increasing number of states passing legislation legalizing access for medical and recreational use. Among cancer patients, cannabis is often used to ameliorate adverse effects of cancer treatment. Data are limited on the extent and type of use among cancer patients during treatment and the perceived benefits and harms. This multicenter survey was conducted to assess the use of cannabis among cancer patients residing in states with varied legal access to cannabis. Methods: A total of 12 NCI-Designated Cancer Centers, across states with varied cannabis-access legal status, conducted surveys with a core questionnaire to assess cannabis use among recently diagnosed cancer patients. Data were collected between September 2021 and August 2023 and pooled across 12 cancer centers. Frequencies and 95% confidence intervals for core survey measures were calculated, and weighted estimates are presented for the 10 sites that drew probability samples. Results: Overall reported cannabis use since cancer diagnosis among survey respondents was 32.9% (weighted), which varied slightly by state legalization status. The most common perceived benefits of use were for pain, sleep, stress and anxiety, and treatment side effects. Reported perceived risks were less common and included inability to drive, difficulty concentrating, lung damage, addiction, and impact on employment. A majority reported feeling comfortable speaking to health-care providers though, overall, only 21.5% reported having done so. Among those who used cannabis since diagnosis, the most common modes were eating in food, smoking, and pills or tinctures, and the most common reasons were for sleep disturbance, followed by pain and stress and anxiety with 60%-68% reporting improved symptoms with use. Conclusion: This geographically diverse survey demonstrates that patients use cannabis regardless of its legal status. Addressing knowledge gaps concerning benefits and harms of cannabis use during cancer treatment is critical to enhance patient-provider communication.

7 August 2024 in Journal of the National Cancer Institute Monographs
Verified
Journal Article
Open access
PDF file
KHKathy J Helzlsouer
Kathy J Helzlsouer
SRSonia M Rosenfield
Sonia M Rosenfield
AFAndrew N Freedman
Andrew N Freedman
AEand Gary L. Ellison
and Gary L. Ellison
Expanding legal access to medical cannabis across the United States increases availability and use of cannabis products to manage cancer-related symptoms and treatment side effects despite the lack of research-based evidence on its potential benefits and harms. To address knowledge gaps in how cancer patients access and use cannabis, their perceived risks and benefits with its use, and whether cancer patients discuss cannabis use with their healthcare providers during treatment, the National Cancer Institute (NCI) supported 12 NCI-designated comprehensive cancer centers to conduct surveys, which included NCI standardized core questions on cannabis use during treatment, among their cancer patient populations. This overview highlights key results from the articles contained in the monograph, which includes a summary of the results of core questions across all centers and reports from individual or groups of cancer centers on survey results related to the sourcing of cannabis, associated cost, behavioral factors associated with cannabis use (such as smoking, drinking, or using other substances), patient-provider communication on cannabis use during treatment, ethnic variations in patterns, sources, and reasons for cannabis use as well as methodologic concerns related to survey data analysis. The results of these surveys of cannabis use after the diagnosis of cancer lay the groundwork for much-needed research to answer the questions of benefits and harms, including potential interactions with cancer treatments for cancer patients.

14 January 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Open access
DDDanielle Daee
Danielle Daee
MBMadison Behm
Madison Behm
PMPamela M. Marcus
Pamela M. Marcus
SRSonia M. Rosenfield
Sonia M. Rosenfield
MRMelissa Rotunno
Melissa Rotunno
EGElizabeth M. Gillanders
Elizabeth M. Gillanders
The secondary use of data can accelerate innovation and drive discoveries, tool development, and reproducibility. Though data sharing can be challenging, policies and incentives can help facilitate and reward these efforts. To maximize the value of data produced through NIH awards, the NIH recently set forth comprehensive, modern data sharing requirements for all funded research with the 2023 NIH Data Management and Sharing Policy. In light of this new comprehensive policy, the NCI’s Division of Cancer Control and Population Sciences (DCCPS) saw an opportunity to reward exemplary data sharers and add an incentive for future data sharing through the development of an award. In 2024, DCCPS established the “Paul Fearn Award for Excellence in Data Sharing” to promote recognition and celebrate data sharing within the field of population sciences. In its inaugural year, the award was given to researchers from four different projects, each exemplary in the sharing of DCCPS-funded work. Each awardee went above and beyond data sharing requirements to make data reusable for others. Their distinct data sharing achievements included making valuable historical datasets available, preparing accessible and easily downloadable datasets, and developing a novel data enclave and/or researcher data platform.

27 May 2026 in Cancer Epidemiology, Biomarkers & Prevention
Verified
Journal Article
Closed access
DCDanielle M. Carrick
Danielle M. Carrick
JTJessica C. Tiner
Jessica C. Tiner
SRSonia M. Rosenfield
Sonia M. Rosenfield
CCCharlisse F. Caga-Anan
Charlisse F. Caga-Anan
JEJoanne W. Elena
Joanne W. Elena
LMLeah E. Mechanic
Leah E. Mechanic
Cancer epidemiology cohorts (CECs) provide key insights into genetic, environmental, lifestyle, and clinical factors influencing cancer development, progression, and outcomes. Engaging communities impacted by research and participants in cohort studies is essential for building trust and ensuring the success of these studies. While the concept of engagement in cancer research is not new, the practice of engagement is evolving towards more rigorous, bidirectional relationships between researchers and communities. Here, we discuss some goals of engagement in CECs supported by the National Cancer Institute, Division of Cancer Control and Population Sciences, Epidemiology and Genomics Research Program, which include: (i) involving community and participant voices in study design and implementation, (ii) providing updates on study progress, (iii) returning value to communities and participants, and (iv) demonstrating appreciation to study participants. This paper also outlines opportunities to enhance engagement activities across cohorts such as expanding the use of digital technologies, continuing to share lessons learned, and supporting report back of findings. Additionally, strengthening evidence base on how to engage communities at all stages of research can foster more meaningful partnerships and ultimately lead to more impactful research and better health outcomes.